PD-1 expression by tumour-associated macrophages inhibits phagocytosis and tumour immunity
Open accessThe DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.
Abstract
Programmed cell death protein 1 (PD-1) is an immune checkpoint receptor that is upregulated on activated T cells for the induction of immune tolerance. Tumour cells frequently overexpress the ligand for PD-1, programmed cell death ligand 1 (PD-L1), facilitating their escape from the immune system. Monoclonal antibodies that block the interaction between PD-1 and PD-L1, by binding to either the ligand or receptor, have shown notable clinical efficacy in patients with a variety of cancers, including melanoma, colorectal cancer, non-small-cell lung cancer and Hodgkin's lymphoma. Although it is well established that PD-1-PD-L1 blockade activates T cells, little is known about the role that this pathway may have in tumour-associated macrophages (TAMs). Here we show that both mouse and human TAMs express PD-1. TAM PD-1 expression increases over time in mouse models of cancer and with increasing disease stage in primary human cancers. TAM PD-1 expression correlates negatively with phagocytic potency against tumour cells, and blockade of PD-1-PD-L1 in vivo increases macrophage phagocytosis, reduces tumour growth and lengthens the survival of mice in mouse models of cancer in a macrophage-dependent fashion. This suggests that PD-1-PD-L1 therapies may also function through a direct effect on macrophages, with substantial implications for the treatment of cancer with these agents.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“and treatment with checkpoint inhibitors targeting PD-1 or PD-L1 increases phagocytosis and reduces tumor growth [329].”
From Drug Resistance in Colorectal Cancer: From Mechanism to Clinic (2022) · cites this paper as [329]
In the citing paper
“In human and mouse CRC tumor models, high levels of PD-1 expression on TAM have low tumor phagocytosis”
From Drug Resistance in Colorectal Cancer: From Mechanism to Clinic (2022) · cites this paper as [329]
In the citing paper
“Tumor-associated macrophages were also recently shown to express PD-1 in both mice and humans with colorectal cancer and to impair macrophage phagocytosis (59).”
From Anti-PD-1 and Anti-CTLA-4 Therapies in Cancer: Mechanisms of Action, Efficacy, and Limitations (2018) · cites this paper as [59]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay-Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,256
The blockade of immune checkpoints in cancer immunotherapy
Pardoll, D. M. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3239 · Cited by 13,838
Safety, activity, and immune correlates of anti–PD-1 antibody in cancer
Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., Powderly, J. D., Carvajal, R. D., Sosman, J. A., Atkins, M. B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200690 · Cited by 12,628
PD-1 and Its Ligands in Tolerance and Immunity
Keir, M. E., Butte, M. J., Freeman, G. J., & Sharpe, A. H. (2008) · Annual Review of Immunology · doi:10.1146/annurev.immunol.26.021607.090331 · Cited by 5,378
Freeman, G. J., Long, A. J., Iwai, Y., Bourque, K., Chernova, T., Nishimura, H., Fitz, L. J., Malenkovich, N., Okazaki, T., Byrne, M. C., et al. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.192.7.1027 · Cited by 5,294
PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma
Ansell, S. M., Lesokhin, A. M., Borrello, I., Halwani, A., Scott, E. C., Gutierrez, M., Schuster, S. J., Millenson, M. M., Cattry, D., Freeman, G. J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1411087 · Cited by 3,560
Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma
Hamid, O., Robert, C., Daud, A., Hodi, F. S., Hwu, W.-J., Kefford, R., Wolchok, J. D., Hersey, P., Joseph, R. W., Weber, J. S., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1305133 · Cited by 3,392
Tumour-educated macrophages promote tumour progression and metastasis
Pollard, J. W. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1256 · Cited by 3,367
Nishimura, H., Nose, M., Hiai, H., Minato, N., & Honjo, T. (1999) · Immunity · doi:10.1016/s1074-7613(00)80089-8 · Cited by 2,749
Cited by
Items 201–300 of 1,001
Minimal PD-1 expression in mouse and human NK cells under diverse conditions
Judge, S. J., Dunai, C., Aguilar, E. G., Vick, S. C., Sturgill, I. R., Khuat, L. T., Stoffel, K. M., Dyke, J. V., Longo, D. L., Darrow, M. A., et al. (2020) · Journal of Clinical Investigation · doi:10.1172/jci133353 · Cited by 152
Macrophage‐Mediated Tumor Cell Phagocytosis: Opportunity for Nanomedicine Intervention
Zhou, X., Liu, X., & Huang, L. (2021) · Advanced Functional Materials · doi:10.1002/adfm.202006220 · Cited by 147
M2 macrophage infiltration into tumor islets leads to poor prognosis in non-small-cell lung cancer
Cao, L., Che, X., Qiu, X., Li, Z., Yang, B., Wang, S., Hou, K., Fan, Y., Qu, X., & Liu, Y. (2019) · Cancer Management and Research · doi:10.2147/cmar.s199832 · Cited by 144
The B7:CD28 family and friends: Unraveling coinhibitory interactions
Burke, K. P., Chaudhri, A., Freeman, G. J., & Sharpe, A. H. (2024) · Immunity · doi:10.1016/j.immuni.2024.01.013 · Cited by 155
Andersen, R. S., Anand, A., Harwood, D. S. L., & Kristensen, B. W. (2021) · Cancers · doi:10.3390/cancers13174255 · Cited by 159
B Cells and Tertiary Lymphoid Structures: Friends or Foes in Cancer Immunotherapy?
Lauss, M., Donia, M., Svane, I. M., & Jönsson, G. B. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-1130 · Cited by 156
The emergence of drug resistance to targeted cancer therapies: Clinical evidence
Sarmento‐Ribeiro, A. B., Scorilas, A., Gonçalves, A. C., Efferth, T., & Trougakos, I. P. (2019) · Drug Resistance Updates · doi:10.1016/j.drup.2019.100646 · Cited by 149
Zhu, X., Liang, R., Lan, T., Ding, D., Huang, S., Shao, J., Zheng, Z., Chen, T., Huang, Y., Liu, J., et al. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-004219 · Cited by 160
Vuong, L. H., Kouverianou, E., Rooney, C. M., McHugh, B. J., Howie, S., Gregory, C. D., Forbes, S. J., Henderson, N. C., Zetterberg, F. R., Nilsson, U. J., et al. (2019) · Cancer Research · doi:10.1158/0008-5472.can-18-2244 · Cited by 155
Wang, G., Chow, R. D.-W., Zhu, L., Bai, Z., Ye, L., Zhang, F., Renauer, P. A., Dong, M. B., Dai, X., Zhang, X., et al. (2020) · Cancer Discovery · doi:10.1158/2159-8290.cd-19-1448 · Cited by 148
Wang, R., He, Z., Cai, P., Zhao, Y., Gao, L., Yang, W., Zhao, Y., Gao, X., & Gao, F. (2019) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.9b01107 · Cited by 142
Bai, X., Guo, Y.-R., Zhao, Z., Li, X., Dai, D.-Q., Zhang, J., Li, Y.-S., & Zhang, C. (2025) · Cancer Letters · doi:10.1016/j.canlet.2025.217772 · Cited by 159
Wang, X., Su, S., Zhu, Y., Cheng, X., Cheng, C., Chen, L., Lei, A., Zhang, L., Xu, Y., Ye, D., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-41470-9 · Cited by 160
Gamma delta T-cell-based immune checkpoint therapy: attractive candidate for antitumor treatment
Gao, Z., Bai, Y., Lin, A., Jiang, A., Zhou, C., Cheng, Q., Liu, Z., Chen, X., Zhang, J., & Luo, P. (2023) · Molecular Cancer · doi:10.1186/s12943-023-01722-0 · Cited by 138
Hossain, M. A., Liu, G., Dai, B., Si, Y., Yang, Q., Wazir, J., Birnbaumer, L., & Yang, Y. (2020) · Medicinal Research Reviews · doi:10.1002/med.21727 · Cited by 154
Next frontier in tumor immunotherapy: macrophage-mediated immune evasion
Qiu, Y., Chen, T., Hu, R., Zhu, R., Li, C., Ruan, Y., Xie, X., & Li, Y. (2021) · Biomarker Research · doi:10.1186/s40364-021-00327-3 · Cited by 158
Klement, J. D., Redd, P. S., Lu, C., Merting, A. D., Poschel, D. B., Yang, D., Savage, N. M., Zhou, G., Munn, D. H., Fallon, P. G., et al. (2023) · Cancer Cell · doi:10.1016/j.ccell.2023.02.005 · Cited by 141
PD-L1 blockade restores CAR T cell activity through IFN-γ-regulation of CD163+ M2 macrophages
Yamaguchi, Y., Gibson, J., Ou, K., Lopez, L. S., Ng, R. H., Leggett, N. A., Jönsson, V. D., Zarif, J. C., Lee, P. P., Wang, X., et al. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-004400 · Cited by 149
miR-21 depletion in macrophages promotes tumoricidal polarization and enhances PD-1 immunotherapy
Xi, J., Huang, Q., Wang, L., Ma, X., Deng, Q., Kumar, M., Zhou, Z., Li, L., Zeng, Z., Young, K. H., et al. (2018) · Oncogene · doi:10.1038/s41388-018-0178-3 · Cited by 143
Beyond T Cells: Understanding the Role of PD-1/PD-L1 in Tumor-Associated Macrophages
Lu, D., Ni, Z., Liu, X., Feng, S., Dong, X., Shi, X., Zhai, J., Mai, S., Jiang, J., Wang, Z., et al. (2019) · Journal of Immunology Research · doi:10.1155/2019/1919082 · Cited by 134
Upton, R., Banuelos, A., Feng, D., Biswas, T., Kao, K., McKenna, K., Willingham, S., Ho, P. Y., Rosental, B., Tal, M. C., et al. (2021) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2026849118 · Cited by 129
Self-citationGromeier, M., Brown, M. C., Zhang, G., Lin, X., Chen, Y., Wei, Z., Beaubier, N. T., Yan, H., He, Y., Desjardins, A., et al. (2021) · Nature Communications · doi:10.1038/s41467-020-20469-6 · Cited by 139
Targeting tumor associated macrophages: The new challenge for nanomedicine
Andón, F. T., Digifico, E., Maeda, A., Erreni, M., Mantovani, A., Alonso, M. J., & Allavena, P. (2017) · Seminars in Immunology · doi:10.1016/j.smim.2017.09.004 · Cited by 136
Neuromuscular Complications of Programmed Cell Death-1 (PD-1) Inhibitors
Kao, J. C., Brickshawana, A., & Liewluck, T. (2018) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-018-0878-7 · Cited by 136
Lai, Y., Wahyuningtyas, R., Aui, S., & Chang, K. (2018) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.14027 · Cited by 135
Hyperprogression under Immunotherapy
Frélaut, M., Tourneau, C. L., & Borcoman, É. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20112674 · Cited by 151
Defects in Macrophage Reprogramming in Cancer Therapy: The Negative Impact of PD-L1/PD-1
Cai, H., Zhang, Y., Wang, J., & Gu, J. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.690869 · Cited by 140
Inhibition of estrogen signaling in myeloid cells increases tumor immunity in melanoma
Chakraborty, B., Byemerwa, J. K., Shepherd, J., Haines, C., Baldi, R., Gong, W., Liu, W., Mukherjee, D., Artham, S., Lim, F., et al. (2021) · Journal of Clinical Investigation · doi:10.1172/jci151347 · Cited by 137
Nano-enhanced immunotherapy: Targeting the immunosuppressive tumor microenvironment
Jin, Y., Huang, Y., Ren, H., Huang, H., Lai, C., Wang, W., Tong, Z., Zhang, H., Wu, W., Liu, C., et al. (2024) · Biomaterials · doi:10.1016/j.biomaterials.2023.122463 · Cited by 142
Functional Expression of Programmed Death-Ligand 1 (B7-H1) by Immune Cells and Tumor Cells
Gibbons Johnson, R. M., & Dong, H. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.00961 · Cited by 129
Toward Biomaterials for Enhancing Immune Checkpoint Blockade Therapy
Fan, Q., Chen, Z., Wang, C., & Liu, Z. (2018) · Advanced Functional Materials · doi:10.1002/adfm.201802540 · Cited by 129
Regulation of CD47 expression in cancer cells
Huang, C.-Y., Ye, Z.-H., Huang, M., & Lu, J. (2020) · Translational Oncology · doi:10.1016/j.tranon.2020.100862 · Cited by 138
Adoptive cellular immunotherapy for solid neoplasms beyond CAR-T
Liu, Q., Li, J., Zheng, H., Yang, S., Hua, Y., Huang, N., Kleeff, J. H., Liao, Q., & Wu, W. (2023) · Molecular Cancer · doi:10.1186/s12943-023-01735-9 · Cited by 144
Dual Targeting of Innate and Adaptive Checkpoints on Tumor Cells Limits Immune Evasion
Liu, X., Liu, L., Ren, Z., Yang, K., Xu, H., Luan, Y., Fu, K., Guo, J., Peng, H., Zhu, M., et al. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.07.062 · Cited by 126
Macrophage-targeted nanomedicine for chronic diseases immunotherapy
Song, Y., Huang, Y., Zhou, F., Ding, J., & Zhou, W. (2022) · Chinese Chemical Letters · doi:10.1016/j.cclet.2021.08.090 · Cited by 120
Extracellular vesicles remodel tumor environment for cancer immunotherapy
Yue, M., Hu, S., Sun, H., Tuo, B., Jia, B., Chen, C., Wang, W., Liu, J., Liu, Y., Sun, Z., et al. (2023) · Molecular Cancer · doi:10.1186/s12943-023-01898-5 · Cited by 119
Immune Checkpoint Inhibition in Head and Neck Cancer
Forster, M. D., & Devlin, M.-J. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00310 · Cited by 135
Rethinking immune checkpoint blockade: ‘Beyond the T cell’
Liu, X., Hogg, G. D., & DeNardo, D. G. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-001460 · Cited by 130
Tumor-associated macrophages are shaped by intratumoral high potassium via Kir2.1
Chen, S., Cui, W., Chi, Z., Xiao, Q., Hu, T., Ye, Q., Zhu, K., Yu, W., Wang, Z., Yu, C., et al. (2022) · Cell Metabolism · doi:10.1016/j.cmet.2022.08.016 · Cited by 132
PD‐1/PD‐L1 inhibitors in haematological malignancies: update 2017
Jelinek, T., Mihalyova, J., Kascak, M., Duras, J., & Hajek, R. (2017) · Immunology · doi:10.1111/imm.12788 · Cited by 122
Chow, R. D., & Chen, S. (2018) · Trends in Cancer · doi:10.1016/j.trecan.2018.03.002 · Cited by 119
Bioresponsive Protein Complex of aPD1 and aCD47 Antibodies for Enhanced Immunotherapy
Chen, Q., Chen, G., Chen, J., Shen, J., Zhang, X., Wang, J., Chan, A., & Gu, Z. (2019) · Nano Letters · doi:10.1021/acs.nanolett.9b00584 · Cited by 122
Targeting tumor-associated macrophages for cancer immunotherapy
Shu, Y., & Cheng, P. (2020) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2020.188434 · Cited by 133
Roles of exosomes in immunotherapy for solid cancers
Lyu, C., Sun, H., Sun, Z., Liu, Y., & Wang, Q. (2024) · Cell Death and Disease · doi:10.1038/s41419-024-06494-z · Cited by 132
Uehara, T., Eikawa, S., Nishida, M., Kunisada, Y., Yoshida, A., Fujiwara, T., Kunisada, T., Ozaki, T., & Udono, H. (2019) · International Immunology · doi:10.1093/intimm/dxy079 · Cited by 118
Tsao, L.-C., Crosby, E. J., Trotter, T. N., Agarwal, P., Hwang, B.-J., Acharya, C. R., Shuptrine, C. W., Wang, T., Wei, J.-P., Yang, X. Y., et al. (2019) · JCI Insight · doi:10.1172/jci.insight.131882 · Cited by 124
Cao, X., Chen, J., Li, B., Dang, J., Zhang, W., Zhong, X., Wang, C., Raoof, M., Sun, Z., Yu, J., et al. (2022) · Science Advances · doi:10.1126/sciadv.abl9171 · Cited by 127
Macrophages Actively Transport Nanoparticles in Tumors After Extravasation
Lin, Z. P., Nguyen, L. N. M., Ouyang, B., MacMillan, P., Ngai, J., Kingston, B. R., Mladjenovic, S. M., & Chan, W. C. W. (2022) · ACS Nano · doi:10.1021/acsnano.1c11578 · Cited by 128
The role of tumor-associated macrophages in osteosarcoma progression – therapeutic implications
Huang, Q., Liang, X., Ren, T., Huang, Y., Zhang, H., Yu, Y., Chen, C., Wang, W., Niu, J., Lou, J., et al. (2021) · Cellular Oncology · doi:10.1007/s13402-021-00598-w · Cited by 118
Tumor-Associated Macrophages: Therapeutic Targets for Skin Cancer
Fujimura, T., Kambayashi, Y., Fujisawa, Y., Hidaka, T., & Aiba, S. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00003 · Cited by 129
Sagwal, S. K., Pasqual-Melo, G., Bodnar, Y., Gandhirajan, R. K., & Bekeschus, S. (2018) · Cell Death and Disease · doi:10.1038/s41419-018-1221-6 · Cited by 125
Macrophage Modification Strategies for Efficient Cell Therapy
Poltavets, A. S., Vishnyakova, P., Elchaninov, A. V., Sukhikh, G. T., & Fatkhudinov, T. (2020) · Cells · doi:10.3390/cells9061535 · Cited by 121
Rao, G., Latha, K., Ott, M., Sabbagh, A., Marisetty, A., Ling, X., Zamler, D. B., Doucette, T. A., Yang, Y., Kong, L., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-4110 · Cited by 129
PD-1 blockade improves Kupffer cell bacterial clearance in acute liver injury
Triantafyllou, E., Gudd, C. L. C., Mawhin, M.-A., Husbyn, H. C., Trovato, F. M., Siggins, M. K., O’Connor, T., Kudo, H., Mukherjee, S. K., Wendon, J. A., et al. (2021) · Journal of Clinical Investigation · doi:10.1172/jci140196 · Cited by 114
Putting the brakes on phagocytosis: “don't‐eat‐me” signaling in physiology and disease
Kelley, S. M., & Ravichandran, K. S. (2021) · EMBO reports · doi:10.15252/embr.202152564 · Cited by 111
The Phagocytic Code Regulating Phagocytosis of Mammalian Cells
Cockram, T. O. J., Dundee, J. M., Popescu, A. S., & Brown, G. C. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.629979 · Cited by 113
Cytokine release syndrome and cancer immunotherapies – historical challenges and promising futures
Shah, D., Soper, B. W., & Shopland, L. S. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1190379 · Cited by 122
Regulation of Ovarian Cancer Prognosis by Immune Cells in the Tumor Microenvironment
Drakes, M. L., & Stiff, P. J. (2018) · Cancers · doi:10.3390/cancers10090302 · Cited by 119
Update on PD-1/PD-L1 Inhibitors in Multiple Myeloma
Jelínek, T., Paiva, B., & Hájek, R. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.02431 · Cited by 124
Wang, Y., Ni, H., Zhou, S., He, K., Gao, Y., Wu, W., Wu, M. H., Wu, Z., Qiu, X., Zhou, Y., et al. (2020) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-020-02679-5 · Cited by 117
Wang, S., Yan, W., Kong, L., Zuo, S., Wu, J., Zhu, C., Huang, H., He, B., Dong, J., & Wei, J. (2023) · Nature Communications · doi:10.1038/s41467-023-39683-z · Cited by 132
Doleschel, D., Hoff, S., Koletnik, S., Rix, A., Zopf, D., Kiessling, F., & Lederle, W. (2021) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-021-02043-0 · Cited by 114
PD-1 immunobiology in systemic lupus erythematosus
Curran, C. S., Gupta, S., Sanz, I., & Sharon, E. (2018) · Journal of Autoimmunity · doi:10.1016/j.jaut.2018.10.025 · Cited by 124
Distinct regional ontogeny and activation of tumor associated macrophages in human glioblastoma
Landry, A., Balas, M., Alli, S. B., Spears, J., & Zador, Z. E. (2020) · Scientific Reports · doi:10.1038/s41598-020-76657-3 · Cited by 121
Yagi, T., Baba, Y., Okadome, K., Kiyozumi, Y., Hiyoshi, Y., Ishimoto, T., Iwatsuki, M., Miyamoto, Y., Yoshida, N., Watanabe, M., et al. (2019) · European Journal of Cancer · doi:10.1016/j.ejca.2019.01.018 · Cited by 123
Yang, Y., Li, L., Jiang, Z., Wang, B., & Pan, Z. (2020) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-020-02641-5 · Cited by 124
Exosomes: Their Role in Pathogenesis, Diagnosis and Treatment of Diseases
Aheget, H., Mazini, L., Martín, F., Belqat, B., Marchal, J. A., & Benabdellah, K. (2020) · Cancers · doi:10.3390/cancers13010084 · Cited by 120
How protons pave the way to aggressive cancers
Swietach, P., Boedtkjer, E., & Pedersen, S. F. (2023) · Nature reviews. Cancer · doi:10.1038/s41568-023-00628-9 · Cited by 124
The immune microenvironment of colorectal cancer
Kennel, K. B., & Greten, F. R. (2025) · Nature reviews. Cancer · doi:10.1038/s41568-025-00872-1 · Cited by 143
Gut microbiota-mediated immunomodulation in tumor
Liu, X., Chen, Y., Zhang, S., & Dong, L. (2021) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-021-01983-x · Cited by 112
Cancer Immunotherapy: A Focus on the Regulation of Immune Checkpoints
Shi, T., Ma, Y., Yu, L., Jiang, J., Shen, S., Hou, Y., & Wang, T. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19051389 · Cited by 115
Innate Immune Checkpoint Inhibitors: The Next Breakthrough in Medical Oncology?
Lentz, R. W., Colton, M. D., Mitra, S. S., & Messersmith, W. A. (2021) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-21-0041 · Cited by 124
Zhai, K., Huang, Z., Huang, Q., Tao, W., Fang, X., Zhang, A., Li, X., Stark, G. R., Hamilton, T. A., & Bao, S. (2021) · Nature Cancer · doi:10.1038/s43018-021-00267-9 · Cited by 118
Targeted inhibition of tumor-derived exosomes as a novel therapeutic option for cancer
Li, Y., Chen, Z.-K., Duan, X., Zhang, H., Xiao, B.-L., Wang, K.-M., & Chen, G. (2022) · Experimental & Molecular Medicine · doi:10.1038/s12276-022-00856-3 · Cited by 117
Turning cold tumors into hot tumors to ignite immunotherapy
Liu, Y., Wang, Y., Wang, S., Li, J., He, W. A., Fan, X.-J., & Wan, X. (2025) · Molecular Cancer · doi:10.1186/s12943-025-02477-6 · Cited by 135
Gunda, V., Gigliotti, B. J., Ndishabandi, D., Ashry, T., McCarthy, M., Zhou, Z., Amin, S., Freeman, G. J., Alessandrini, A., & Parangi, S. (2018) · British Journal of Cancer · doi:10.1038/s41416-018-0296-2 · Cited by 118
Research trends in pharmacological modulation of tumor‐associated macrophages
Wang, N., Wang, S., Wang, X., Zheng, Y., Yang, B., Zhang, J., Pan, B., Gao, J., & Wang, Z. (2021) · Clinical and Translational Medicine · doi:10.1002/ctm2.288 · Cited by 107
Zhou, X., Ni, Y., Liang, X., Lin, Y., An, B., He, X., & Zhao, X. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.915094 · Cited by 145
Zhou, W., Zhang, M., Liu, C., Kang, Y., Wang, J., & Yang, X. (2019) · Journal of Cellular Physiology · doi:10.1002/jcp.28884 · Cited by 110
Checkpoint blockade in Hodgkin and non-Hodgkin lymphoma
Merryman, R. W., Armand, P. A., Wright, K., & Rodig, S. J. (2017) · Blood Advances · doi:10.1182/bloodadvances.2017012534 · Cited by 117
Application of advances in endocytosis and membrane trafficking to drug delivery
Ju, Y., Guo, H., Edman, M. C., & Hamm‐Alvarez, S. F. (2020) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2020.07.026 · Cited by 116
Di Tacchio, M., Macas, J., Weissenberger, J., Sommer, K., Bähr, O., Steinbach, J. P., Senft, C., Seifert, V., Glas, M., Herrlinger, U., et al. (2019) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-18-0865 · Cited by 104
Tumor-Associated Macrophages (TAMs): A Critical Activator In Ovarian Cancer Metastasis
Yin, M., Shen, J., Yu, S., Jing, F., Zhu, X., Zhao, J., Zhai, L., Sadhukhan, A., & Zhou, J. (2019) · OncoTargets and Therapy · doi:10.2147/ott.s216355 · Cited by 111
Chen, D., Barsoumian, H. B., Yang, L., Younes, A. I., Verma, V., Hu, Y., Menon, H., Wasley, M., Masropour, F., Mosaffa, S., et al. (2020) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-19-0744 · Cited by 107
“First, because SHP-2 is a negative target in antitumor immunity, SHP-2þM1 TAMs would not have stronger antitumor effects than SHP-2 M1 TAMs, as is the case for PD-1þmacrophages and PD-1 macrophages (35).”
BackgroundMolecular Mechanism of Tumor Cell Immune Escape Mediated by CD24/Siglec-10
Yin, S.-S., & Gao, F. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01324 · Cited by 116
Li, H., Somiya, M., & Kuroda, S. (2021) · Biomaterials · doi:10.1016/j.biomaterials.2020.120601 · Cited by 106
CD47‐SIRPα blocking‐based immunotherapy: Current and prospective therapeutic strategies
Bouwstra, R., van Meerten, T., & Bremer, E. (2022) · Clinical and Translational Medicine · doi:10.1002/ctm2.943 · Cited by 120
Mu, X., Zhang, M., Wei, A., Yin, F., Wang, Y., Hu, K., & Jiang, J. (2021) · Nanoscale · doi:10.1039/d0nr08024a · Cited by 105
Mathematical modeling of tumor-associated macrophage interactions with the cancer microenvironment
Mahlbacher, G. E., Curtis, L. T., Lowengrub, J. S., & Frieboes, H. B. (2018) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-017-0313-7 · Cited by 112
Yeong, J. P.-S., Lim, J. C. T., Lee, B. T. K., Li, H., Ong, C. C. H., Thike, A. A., Yeap, W. H., Yang, Y. L., Lim, A. Y. H., Tay, T. K. Y., et al. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0499-y · Cited by 108
Racioppi, L., Nelson, E. R., Huang, W., Mukherjee, D., Lawrence, S. A., Lento, W., Masci, A. M., Jiao, Y., Park, S., York, B., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-10424-5 · Cited by 104
A new era of cancer immunotherapy: combining revolutionary technologies for enhanced CAR-M therapy
Li, N., Geng, S., Dong, Z., Jin, Y., Ying, H., Li, H., & Shi, L. (2024) · Molecular Cancer · doi:10.1186/s12943-024-02032-9 · Cited by 120
Tumor-associated macrophages: a short compendium
Prenen, H., & Mazzone, M. (2019) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-018-2997-3 · Cited by 108
The role of PD-1/PD-L1 axis and macrophage in the progression and treatment of cancer
Cai, J., Qi, Q., Qian, X., Han, J. G., Zhu, X., Zhang, Q., & Xia, R. (2019) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-019-02879-2 · Cited by 106
Zerdes, I., Wallerius, M., Sifakis, E. G., Wallmann, T., Betts, S., Bartish, M., Tsesmetzis, N., Tobin, N. P., Coucoravas, C., Bergh, J. C. S., et al. (2019) · Cancers · doi:10.3390/cancers11101479 · Cited by 110
Ju, Q., Li, X., Zhang, H., Yan, S., Li, Y., & Zhao, Y. (2020) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2020/3580719 · Cited by 116
Deshpande, R. P., Sharma, S., & Watabe, K. (2020) · Cancers · doi:10.3390/cancers12102983 · Cited by 108
He, W., Leng, X., Mao, T., Luo, X., Zhou, L., Yan, J., Peng, L., Fang, Q., Liu, G., Wei, X., et al. (2022) · The Oncologist · doi:10.1093/oncolo/oyab011 · Cited by 102
Individualized precision treatment: Targeting TAM in HCC
Li, Z., Wu, T., Zheng, B. J., & Chen, L. (2019) · Cancer Letters · doi:10.1016/j.canlet.2019.05.019 · Cited by 106
Pollari, M., Brück, O. E., Pellinen, T. S., Vähämurto, P., Karjalainen‐Lindsberg, M., Mannisto, S., Kallioniemi, O., Kellokumpu‐Lehtinen, P., Mustjoki, S. M., Leivonen, S., et al. (2018) · Haematologica · doi:10.3324/haematol.2018.197194 · Cited by 105
Metadata
- Authors
- Gordon, S. R., Maute, R. L., Dulken, B. W., Hutter, G., George, B. M., McCracken, M. N., Gupta, R., Tsai, J. M., Sinha, R., Corey, D., Ring, A. M., Connolly, A. J., & Weissman, I. L.
- Affiliations
- Stanford Medicine (US)
- Institute for Stem Cell Biology and Regenerative Medicine (US)
- Yale University (US)
- Corresponding author
- Weissman, Irving L.
- ORCID
- Venue
- Nature
- Published
- 2017-05
- Volume
- 545
- Issue
- 7655
- Pages
- 495-499
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- PMC
- PMC5931375
- OpenAlex
- W2615301036
- Cited by
- 2,247
- References
- 34
- Citations by year
- 2026: 167 · 2025: 261 · 2024: 303 · 2023: 298 · 2022: 309 · 2021: 299 · 2020: 264 · 2019: 158 · 2018: 135 · 2017: 51
- FWCI
- 75.25
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Funders
- National Science Foundation
- Cancer Research Institute
- A.P. Giannini Foundation
- Giannini Foundation of Agricultural Economics
- Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung (155336)
- National Institutes of Health (1s10rr026780-01)
- National Cancer Institute (R01CA086017, P30CA124435)
- National Institute of General Medical Sciences (T32GM007365)
- National Institute of Arthritis and Musculoskeletal and Skin Diseases (T32AR050942)
- National Center for Research Resources (1S10RR02678001, 1S10RR026780, S10 RR026780)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Immune cells in cancer
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Immunology and Microbiology › Immunology › Phagocytosis and Immune Regulation
- Keywords
- PD-1, tumour-associated macrophages, PD-L1, phagocytosis, immune checkpoint blockade, tumour immunity, cancer immunotherapy, tumour-infiltrating macrophages
- MeSH terms
- Animals, Colonic Neoplasms, Disease Models, Animal, Female, Humans, Macrophages, Male, Mice, Inbred BALB C, Neoplasm Staging, Phagocytosis, Xenograft Model Antitumor Assays, Cell Line, Tumor, Cell Proliferation, Mice, B7-H1 Antigen, Programmed Cell Death 1 Receptor
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.